Fintel reports that BlackRock has filed a 13G/A form with the SEC disclosing ownership of 8.00MM shares of Relay Therapeutics Inc (RLAY). This represents 6.6% of the company.
In their previous filing dated February 4, 2022 they reported 5.99MM shares and 5.50% of the company, an increase in shares of 33.44% and an increase in total ownership of 1.10% (calculated as current - previous percent ownership).
Analyst Price Forecast Suggests 76.81% Upside
As of January 31, 2023, the average one-year price target for Relay Therapeutics is $37.94. The forecasts range from a low of $16.16 to a high of $47.25. The average price target represents an increase of 76.81% from its latest reported closing price of $21.46.
The projected annual revenue for Relay Therapeutics is $16MM, an increase of 863.36%. The projected annual EPS is $-3.11.
Fund Sentiment
There are 426 funds or institutions reporting positions in Relay Therapeutics. This is an increase of 5 owner(s) or 1.19%.
Average portfolio weight of all funds dedicated to US:RLAY is 0.2134%, an increase of 23.1552%. Total shares owned by institutions increased in the last three months by 2.97% to 131,551K shares.
What are large shareholders doing?
Sb Investment Advisers holds 27,904,963 shares representing 23.08% ownership of the company. No change in the last quarter.
Jpmorgan Chase & holds 5,018,487 shares representing 4.15% ownership of the company. In it's prior filing, the firm reported owning 4,942,262 shares, representing an increase of 1.52%. The firm increased its portfolio allocation in RLAY by 39.79% over the last quarter.
Casdin Capital holds 4,683,432 shares representing 3.87% ownership of the company. In it's prior filing, the firm reported owning 4,068,574 shares, representing an increase of 13.13%. The firm increased its portfolio allocation in RLAY by 19.44% over the last quarter.
Price T Rowe Associates holds 4,561,363 shares representing 3.77% ownership of the company. In it's prior filing, the firm reported owning 5,300,307 shares, representing a decrease of 16.20%. The firm decreased its portfolio allocation in RLAY by 33.58% over the last quarter.
Bvf holds 4,339,521 shares representing 3.59% ownership of the company. In it's prior filing, the firm reported owning 4,384,805 shares, representing a decrease of 1.04%. The firm increased its portfolio allocation in RLAY by 13.05% over the last quarter.
Relay Therapeutics Background Information
(This description is provided by the company.)
Relay Therapeutics, Inc. operates as a biotechnology company. The Company develops durgs for the treatment of cancer. Relay Therapeutics serves customers in the United States.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
